The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten with a federal deadline to halt off-brand products.

The Novo Nordisk Foundation has pledged up to DKK 380 million ($57.76 million) to the World Health Organization (WHO) to ...

Novo Nordisk is teaming up with Septerna to develop new pills to treat obesity, type 2 diabetes, and other metabolic diseases.

Lazard acted as the exclusive financial advisor to Paratek Pharmaceuticals, and Skadden, Arps, Slate, Meagher & Flom LLP served as its legal advisor. Evercore acted as the exclusive financial advisor ...

BMO Capital Markets reaffirmed its “Market Perform” rating and $64.00 price target for Novo Nordisk A/S (NYSE:NVO) following ...

In addition to voluntary pledges, WHO member states last year approved an increase in assessed contributions. This year also, ...

BioSpace examines the busiest corporate venture capital arms in the pharmaceutical industry. Novo Holdings, which made ...

In the near term, commercial efforts might raise the chances that new patients are prescribed Novo Nordisk’s drug, assuming ...

"I'm not going to second-guess myself."Wegovy belongs to a pricey class of drugs called GLP-1s (short for glucagon-like ...

Online weight-loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk’s Wegovy as the U.S.

Novo Nordisk (NYSE: NVO) stock jumped 3% through 10:55 a.m. Tuesday on some potentially positive news in the GLP-1 weight ...